Elevar Therapeutics, Inc.

Subsidiary of HLB Co., Ltd. (028300)

Assets

(3 total)
3Total Assets
1Approved
2Phase 3 / Filed
0Phase 1–2 / Early
6Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
lirafugratinib(Lyrfigtu)
Approved
FGFR2Small molecule
Biliary Tract Cancer
Cholangiocarcinoma
Phase 3
VEGFR2Small molecule
Non-Small Cell Lung CancerHepatocellular Carcinoma
Phase 3
PD-1Monoclonal antibody
Non-Small Cell Lung CancerCervical CancerHepatocellular CarcinomaGastric CancerNasopharyngeal Carcinoma

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
July 2027 (1)
ApatinibPhase 2Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk
Est. primary completion 2027-07 · NCT07682272 · CT.gov ↗
What to watch
September 2027 (1)
lirafugratinib · LyrfigtuPhase 2FGFR2 Gene Fusion/Rearrangement, Other Solid Tumors, Adult
Est. primary completion 2027-09 · NCT07359820 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(6)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

9 April 2027FDA action dateCamrelizumabPDUFA target action date for rivoceranib + camrelizumab (first-line uHCC)
US, FDA · Source ↗

Recent

5 November 2026Filing acceptedCamrelizumabFDA accepts the resubmitted rivoceranib + camrelizumab applications (first-line uHCC)
US, FDA · Source ↗
9 October 2026Filing submittedApatinibRivoceranib NDA resubmitted to the FDA after July 2026 CRL
US, FDA · Elevar Therapeutics, Inc. · Source ↗
23 September 2026ApprovallirafugratinibFDA approves Lyrfigtu in previously treated FGFR2-altered cholangiocarcinoma
US, FDA · Elevar Therapeutics, Inc. · Source ↗
10 July 2026Complete response letterApatinibFDA issues complete response letter for rivoceranib + camrelizumab NDA (first-line uHCC)
US, FDA · Elevar Therapeutics, Inc. · Source ↗
10 July 2026Complete response letterCamrelizumabFDA issues complete response letter for rivoceranib + camrelizumab (first-line uHCC)
US, FDA · Elevar Therapeutics, Inc. · Source ↗

Financial reports

No financial reports recorded.